Author:
Mwacalimba Kennedy,Sears Derek,Brennan Christopher,Poulsen Nautrup Barbara,Sheehy Jenifer,Smith Kristine,Adolph Christopher
Abstract
Abstract
Background
Compliance failure with administration of heartworm (HW) disease preventives has been reported as the main contributor to HW disease incidence in medicalized dogs. This study aimed to evaluate purchase compliance with different canine HW preventive products in the USA.
Methods
Anonymized transaction data from clinics throughout the USA served as the basis for two retrospective analyses. We first examined the monthly equivalent doses of HW preventive purchases from clinics that had implemented extended-release moxidectin injectables ProHeart® 6 (PH6) and/or ProHeart® 12 (PH12) compared to clinics that prescribed monthly HW preventatives (MHWP) only. In the second analysis, the purchase compliance in practices that dispensed only flea and tick (FT) and HW products separately but did not dispense combination products (dual-therapy practices) was compared to the purchase compliance with the combination product Simparica Trio® (sarolaner, moxidectin, and pyrantel chewable tablets), purchased in clinics having implemented combination therapy in their formulary (combination-therapy practices). In both analyses, the numbers of monthly doses dispensed annually per dog were calculated.
Results
Transaction data from 3,539,990 dogs in 4615 practices were included in the first analysis. In dogs administered PH12 or PH6, the numbers of monthly equivalent doses were 12 and 8.1, respectively. In both clinic types, the average annual number of MHWP doses totaled 7.3. In the second analysis, a total of 919 practices were identified as combination-therapy practices and 434 as dual-therapy-only practices. A total of 246,654 dogs (160,854 dogs in dual-therapy practices and 85,800 dogs in combination-therapy practices) were included in the calculation of the average annual number of monthly doses, which totaled 6.8 (HW preventive products) and 4.4 (FT products) in dual-therapy practices compared to 7.2 months for both FT and HW preventives with Simparica Trio® across both practice types.
Conclusions
The injectable HW preventive PH12 is the only product that provides 12 months of heartworm disease prevention in a single veterinarian-administered injection. When choosing a monthly preventive, the combination therapy was associated with a greater purchase compliance compared with FT and HW products being dispensed separately.
Graphical Abstract
Publisher
Springer Science and Business Media LLC
Subject
Infectious Diseases,Parasitology
Reference17 articles.
1. American Heartworm Society. Current Canine Guidelines for the Prevention, Diagnosis, and Management of Heartworm (Dirofilaria immitis) Infection in Dogs. 2020. https://www.heartwormsociety.org/veterinary-resources/american-heartworm-society-guidelines. Accessed 07 Nov 2022.
2. American Heartworm Society. AHS Announces findings of new heartworm incidence survey. 2017. https://www.heartwormsociety.org/in-the-news/347-ahs-announces-findings-of-new-heartworm-incidence-survey?highlight=WyJpbmNpZGVuY2UiXQ==. Accessed 07 Nov 2022.
3. Savadelis MD, McTier TL, Kryda K, Maeder SJ, Woods DJ. Moxidectin: heartworm disease prevention in dogs in the face of emerging macrocyclic lactone resistance. Parasit Vectors. 2022;15:82.
4. Atkins CE, Murray MJ, Olavessen LJ, Burton KW, Marshall JW, Brooks CC. Heartworm “lack of effectiveness” claims in the Mississippi delta: computerized analysis of owner compliance - 2004–2011. Vet Parasitol. 2014;206:106–13.
5. Zoetis Inc. Simparica Trio [Internet]. https://www2.zoetisus.com/content/_assets/docs/Petcare/simparica-trio-pi.pdf. Accessed 07 Nov 2022.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献